Related content

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

By Sand Peter   Miklos John   Ritter Henry   Appell Rodney  

International Urogynecology Journal, Vol. 15, Iss. 4, 2004-08 ,pp. : 243-248

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of Dry Mouth in Women Treated with Extended-Release Formulations of Oxybutynin or Tolterodine for Overactive Bladder

By Armstrong Robert   Luber Karl   Peters Kenneth  

International Urology and Nephrology, Vol. 37, Iss. 2, 2005-06 ,pp. : 247-252

Springer Publishing Company

Access to resources Recommend Favorite

Long-Term Safety, Tolerability and Efficacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder

By Kreder K.   Mayne C.   Jonas U.  

European Urology, Vol. 41, Iss. 6, 2002-06 ,pp. : 588-595

Elsevier

Access to resources Recommend Favorite

Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial

By Homma Y.  

World Journal of Urology, Vol. 22, Iss. 4, 2004-08 ,pp. : 251-256

Springer Publishing Company

Access to resources Recommend Favorite

A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden

By Peeker Ralph   Samsioe Gööran   Kowalski Jan   Andersson Ann-Sofie   Bergqvist Agneta  

Scandinavian Journal of Urology and Nephrology, Vol. 44, Iss. 3, 2010-04 ,pp. : 138-146

Informa Healthcare

Access to resources Recommend Favorite